Expression of ARID1B Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma.
Expression of ARID1B Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma.
复制标题
ARID1B 的表达与不良结果相关，并预测膀胱尿路上皮癌辅助化疗的益处
DOI：
10.7150/jca.19109
复制
发表时间：
2017
影响因子：
3.9
通讯作者：
Ye D
中科院分区：
文献类型：
--
作者：
Wang B;Xie H;Ma C;Zhang G;Gan H;Wang Q;Liu X;Zhu Y;Zhu Y;Shi G;Zhang H;Dai B;Shen Y;Ye D
背景ARID1B是SWI/SNF染色质重塑复合体中与ARID1A互斥的异构体，近年来被发现是多种癌症的主要突变基因。本研究旨在确定ARID1B表达与膀胱癌患者预后的关系，以及辅助化疗的益处。方法建立从本中心连续招募的143例膀胱癌患者的组织芯片。免疫组织化学方法检测ARID1B的表达及其与预后的关系。并对其临床病理因素进行评价。结果ARID1B的表达与肿瘤大小(P=0.015)、T分期(P=0.027)、淋巴结状态(P=0.030)、TNM分期(P=0.040)、总生存期(P<；0.001)和无进展生存期(P=0.043)显著相关。此外，ARID1B高表达是OS不良的独立指标(P=0.022)。包含ARID1B的预测模型显示出比BASE模型更好的预测准确性。最重要的是，在ARID1B低表达的患者中观察到的辅助化疗的益处优于ARID1B高表达的患者。结论ARID1B可作为判断膀胱尿路上皮癌预后的生物标志物。此外，ARID1B可能是在高危亚组中选择辅助化疗患者的预测标记物。
Background ARID1B, which exists as a mutually exclusive isoform with ARID1A in the SWI/SNF chromatin remodeling complex, has been recently identified as a major mutant gene in a wide variety of cancers. The present study aimed to determine the association between ARID1B expression and outcomes, as well as the benefit from adjuvant chemotherapy in patients with bladder cancer. Methods Tissue microarrays of 143 consecutively recruited patients with bladder cancer from our center were created. Immunohistochemistry was performed to assess the expression of ARID1B and its association with outcomes. Clinicopathological factors were also evaluated. Results ARID1B expression was significantly associated with tumor size (P=0.015), T stage (P=0.027), lymph node status (P=0.030), TNM stage (P=0.040), overall survival (P<0.001), and progression-free survival (P=0.043). Furthermore, high expression of ARID1B was an independent indicator of poor OS (P=0.022). The prognostic model containing ARID1B showed a better predictive accuracy than the bench models. Most importantly, the benefit of adjuvant chemotherapy observed in patients with low ARID1B expression was superior to that observed in patients with high ARID1B expression. Conclusions Our study suggests that ARID1B can serve as a prognostic biomarker of bladder urothelial carcinoma. Additionally, ARID1B might be a predictive marker for selecting patients for adjuvant chemotherapy in the high-risk subgroup.
登录
查看更多内容
影响因子：
8.8
作者：
Khursheed M;Kolla JN;Kotapalli V;Gupta N;Gowrishankar S;Uppin SG;Sastry RA;Koganti S;Sundaram C;Pollack JR;Bashyam MD
通讯作者：
Bashyam MD
影响因子：
23.4
作者：
Witjes, J. Alfred;Comperat, Eva;Sherif, Amir
通讯作者：
Sherif, Amir
影响因子：
6.6
作者：
Freiha, F;Reese, J;Torti, FM
通讯作者：
Torti, FM
影响因子：
30.8
作者：
Santen, Gijs W. E.;Aten, Emmelien;Kriek, Marjolein
通讯作者：
Kriek, Marjolein
影响因子：
4.8
作者：
Inoue, H;Furukawa, T;Tanese, N
通讯作者：
Tanese, N